Delee careers

At Delee, we have created the CytoCatch™️ isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.

For the assay, a single blood tube along with several reagents are loaded on the CytoCatch™ isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The unit has an outstanding performance, it has recovery rates above 96% when processing 7.5 mL blood samples spiked with tumor cells from prostate, breast, and colorectal cancer cell lines. Once captured, the CytoCatch™ isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis with the CytoCatch™ imaging system, which possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. Furthermore, the collected cells are compatible with traditional molecular biology techniques and next-generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs. Finally, the treating physician will get a report with the corresponding results.

We are backed by Y Combinator and StartX; and so far, we have raised over $2.6 million USD in funding. Our company has a multidisciplinary team of scientists and engineers working full-time and has a strong advisory board composed of people with experience in the scientific and clinical fields, as well as in the business managing side, which is of utmost importance to ensure the success of our company.

We are certain that our technology will revolutionize how cancer is diagnosed and managed. Join us a become part of the solution!